866-997-4948(US-Canada Toll Free)

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Metabolic Disorders

No. of Pages : 40 Pages


Global Markets Directs, \'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome). Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome).
  • A review of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Overview 6
Therapeutics Development 7
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Overview 7
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis 8
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics under Development by Companies 9
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Products under Development by Companies 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Companies Involved in Therapeutics Development 14
Lentigen Corporation 14
Shire Plc 15
Green Cross Corporation 16
JCR Pharmaceuticals Co., Ltd. 17
ArmaGen Technologies, Inc. 18
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Assessment by Therapeutic Class 26
Drug Profiles 28
idursulfase - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
JR-032 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AGT-182 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LG-1041 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
idursulfase - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Recent Pipeline Updates 33
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects 35
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Product Development Milestones 36
Featured News & Press Releases 36
Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 36
Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press 36
Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome 37
Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase 38
Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome 38

Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Table


Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), H2 2013 7
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Stage Development, H2 2013 11
Comparative Analysis by Unknown Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Lentigen Corporation, H2 2013 14
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Shire Plc, H2 2013 15
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Green Cross Corporation, H2 2013 16
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2013 17
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by ArmaGen Technologies, Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 20
Number of Products by Stage and Mechanism of Action, H2 2013 21
Number of Products by Stage and Route of Administration, H2 2013 23
Number of Products by Stage and Molecule Type, H2 2013 25
Number of Products by Stage and Therapeutic Class, H2 2013 27
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics - Recent Pipeline Updates, H2 2013 33
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects, H2 2013 35

List of Chart


Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), H2 2013 7
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 21
Number of Products by Top 10 Route of Administration, H2 2013 22
Number of Products by Stage and Top 10 Route of Administration, H2 2013 23
Number of Products by Top 10 Molecule Type, H2 2013 24
Number of Products by Stage and Top 10 Molecule Type, H2 2013 25
Number of Products by Top 10 Therapeutic Class, H2 2013 26
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *